Liposarcoma Treatment Market : Global Industry Analysis and Forecast 2016 - 2022
- Submitted by: justinbarnes123
- Views: 76
- Category: Other
- Date Submitted: 05/02/2016 02:33 AM
- Pages: 4
- Report this Essay
Liposarcoma Treatment Market : Global Industry Analysis
and Forecast 2016 - 2022
Persistence Market Research
Liposarcoma Treatment Market : Global
Industry Analysis and Forecast 2016 - 2022
Persistence Market Research
1
Liposarcoma Treatment Market : Global Industry Analysis
and Forecast 2016 - 2022
Persistence Market Research Released New Market Report on “Liposarcoma Treatment
Market : Global Industry Analysis and Forecast 2016 - 2022”.
Liposarcoma is a cancer of fat cells lying deep within the soft tissues, typically in
retroperitoneum or thighs. According to WHO, liposarcoma is the most common type of
sarcomas (cancer of soft tissue) and accounts for approximately 17-20% of all cases of
sarcoma. However, WHO classifies liposarcoma in the rare diseases as the incidence rate of
the disease is as low as 2.5 per Mn population. Liposarcoma most commonly occurs in the
middle age or adults above the age of 40 and it can be well diagnosed with the help of excision
biopsy. Liposarcoma can be of four types viz. well differentiated liposarcoma, myxoid
liposarcoma, pleomorphic liposarcoma and dedifferentiated liposarcoma. The most common
drugs used for the treatment of liposarcoma include ifosfamide and doxorubicin. Ifosfamide is
often prescribed in combination with uromitexan in order to prevent bladder irritation and internal
bleeding. Moreover, cisplatin, vincristine, etoposide, gemcitabine, docetaxel etc. can be used to
prevent the recurrence of liposarcoma.
The market for liposarcoma is highly fragmented with large number of generic manufacturers.
The global market for liposarcoma treatment is expected to grow moderately over the forecast
period owing to low incidence rate of the disease. Some other factors which are anticipated to
influence growth of global liposarcoma treatment market include lifestyle changes, incidence of
genetic disorders, growing awareness through liposarcoma genome project etc. However, high
cost of the treatment can be the major...
and Forecast 2016 - 2022
Persistence Market Research
Liposarcoma Treatment Market : Global
Industry Analysis and Forecast 2016 - 2022
Persistence Market Research
1
Liposarcoma Treatment Market : Global Industry Analysis
and Forecast 2016 - 2022
Persistence Market Research Released New Market Report on “Liposarcoma Treatment
Market : Global Industry Analysis and Forecast 2016 - 2022”.
Liposarcoma is a cancer of fat cells lying deep within the soft tissues, typically in
retroperitoneum or thighs. According to WHO, liposarcoma is the most common type of
sarcomas (cancer of soft tissue) and accounts for approximately 17-20% of all cases of
sarcoma. However, WHO classifies liposarcoma in the rare diseases as the incidence rate of
the disease is as low as 2.5 per Mn population. Liposarcoma most commonly occurs in the
middle age or adults above the age of 40 and it can be well diagnosed with the help of excision
biopsy. Liposarcoma can be of four types viz. well differentiated liposarcoma, myxoid
liposarcoma, pleomorphic liposarcoma and dedifferentiated liposarcoma. The most common
drugs used for the treatment of liposarcoma include ifosfamide and doxorubicin. Ifosfamide is
often prescribed in combination with uromitexan in order to prevent bladder irritation and internal
bleeding. Moreover, cisplatin, vincristine, etoposide, gemcitabine, docetaxel etc. can be used to
prevent the recurrence of liposarcoma.
The market for liposarcoma is highly fragmented with large number of generic manufacturers.
The global market for liposarcoma treatment is expected to grow moderately over the forecast
period owing to low incidence rate of the disease. Some other factors which are anticipated to
influence growth of global liposarcoma treatment market include lifestyle changes, incidence of
genetic disorders, growing awareness through liposarcoma genome project etc. However, high
cost of the treatment can be the major...